ZERO WINTERDEAL 2025: Bis zu 300 € Prämie + Gratis-Aktie + finanzen.net MSCI World-ETF - Jetzt informieren!

Original-Research: SYGNIS AG (von GBC AG): BUY

26.11.15 15:00 Uhr

Original-Research: SYGNIS AG - von GBC AG

Einstufung von GBC AG zu SYGNIS AG

Unternehmen: SYGNIS AG

Wer­bung

ISIN: DE000A1RFM03

Anlass der Studie: Research Report (Update)

Empfehlung: BUY

Kursziel: 3.75 Euro

Kursziel auf Sicht von: End FY 2016

Letzte Ratingänderung:

Analyst: Cosmin Filker, Felix Gode, CFA

Product launch plan fulfilled; sales network expanded; capital increase

significantly improves financial scope for further sales expansion

Wer­bung

In its 2015 nine-month report, SYGNIS AG presented figures that were within

our expectations. The continued low revenue level of EUR0.31m (9M/14:

EUR0.30m) reflects the fact that its two most important product lines,

TruePrimeTM and SunScriptTM, are still in the early marketing phase. Both

product lines were only globally launched in the current financial year

2015, meaning, that they first have to go through a typical lead time.

Wer­bung

Based on the continued low revenue contributions, despite a recorded

increase in kits sold to 149 in Q3 2015 (1 HY 2015: 102), in the nine-month

figures for 2015, SYGNIS AG still posted a negative EBIT of -EUR2.71m

(9M/14: EUR-2.27m), as expected. This includes extraordinary expenses

related to the optimisation of administrative structures (reduction of

workforce, relocation within Heidelberg and transformation of Heidelberg

into a production site) totalling EUR0.36m. Without extraordinary effects,

SYGNIS AG would have achieved near constant development of the EBIT

(adjusted EBIT: -EUR2.35m).

In the period under review, SYGNIS AG therefore focused on launching its

two new product lines and expanding its sales network, as an important

component of its own sales. With the launch of five kits within the two

product lines, the company fulfilled its product launch plan. In addition

to Germany, the products are currently also being sold in Spain, France,

Belgium, Canada, the UK, Australia, China, Finland, Ireland, Switzerland,

Taiwan and Japan. They can also be purchased directly from the newly

established online shop.

A further important aspect is SYGNIS AG's cash position, given the

continued low revenues and the associated negative cash flow. As at

30/09/2015, the company's cash position totals EUR0.61m (31/12/14:

EUR3.76m) and will significantly increase following a successful capital

increase. By issuing 3.86m new shares at a subscription price of EUR1.90

per share (7:2 subscription ratio), the company aims to increase its equity

by EUR7.33m. The company aims to use the cash proceeds primarily to finance

operating business until break-even is achieved, at the latest on 31

December 2017. Furthermore, SYGNIS AG plans to partially repay promotional

loans and retain liquidity to increase financial flexibility.

We have not changed our last published forecasts (see the research study

dated 08/10/2015) and therefore have not yet included the currently ongoing

capital increase (pre-money). After completion of the capital increase, we

will update our forecast planning to include the cash proceeds.

In view of these unchanged forecasts, we reaffirm the price target

calculated as part of the DCF valuation model of EUR3.75 per share

(pre-money) as at the end of financial year 2016. Based on the current

price level, our previously issued BUY rating remains unchanged.

Die vollständige Analyse können Sie hier downloaden:

http://www.more-ir.de/d/13409.pdf

Kontakt für Rückfragen

Jörg Grunwald

Vorstand

GBC AG

Halderstraße 27

86150 Augsburg

0821 / 241133 0

research@gbc-ag.de

++++++++++++++++

Offenlegung möglicher Interessenskonflikte nach §34b Abs. 1 WpHG und FinAnV Beim oben analysierten Unternehmen ist folgender möglicher Interessenkonflikt gegeben: (4,5a,5b,6a,10,11); Einen Katalog möglicher Interessenkonflikte finden Sie unter:

http://www.gbc-ag.de/de/Offenlegung.htm

+++++++++++++++

-------------------übermittelt durch die EQS Group AG.-------------------

Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw.

Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung

oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.

Nachrichten zu Expedeon (ex Sygnis)

Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv

Wer­bung

Analysen zu Expedeon (ex Sygnis)

DatumRatingAnalyst
14.11.2019Expedeon (ex Sygnis) KaufenGBC
10.10.2019Expedeon (ex Sygnis) KaufenGBC
24.07.2019Expedeon (ex Sygnis) KaufenGBC
22.06.2018SYGNIS KaufenGBC
09.11.2017SYGNIS KaufenGBC
DatumRatingAnalyst
14.11.2019Expedeon (ex Sygnis) KaufenGBC
10.10.2019Expedeon (ex Sygnis) KaufenGBC
24.07.2019Expedeon (ex Sygnis) KaufenGBC
22.06.2018SYGNIS KaufenGBC
09.11.2017SYGNIS KaufenGBC
DatumRatingAnalyst
07.12.2012SYGNIS Pharma holdClose Brothers Seydler Research AG
01.08.2012SYGNIS Pharma holdClose Brothers Seydler Research AG
28.08.2006LION bioscience nicht verkaufenSdK AktionärsNews
13.07.2006LION bioscience haltenDer Aktionär
01.06.2006LION bioscience Stopp nachziehenDer Aktionär
DatumRatingAnalyst
19.12.2011SYGNIS Pharma sellClose Brothers Seydler Research AG

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Expedeon (ex Sygnis) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen